Dieter Natlacen

New Court, new approaches: How the UPC is reshaping pharmaceutical patent litigation

by multiple authors

Cabinet decision on the Statutory Health Insurance Contribution Stabilization Act – Financial burdens on German pharmaceutical companies

by Dr. Daniel Tietjen and Ennio Schwind, LL.M. Eur.

Federal Administrative Court on the Delineation between Substance-Based Medical Devices and Medicinal Products

by Daniel Dietrich and Dr. Daniel Tietjen

CJEU Advocate General on Distributors’ Obligations for Medical Devices

by Dr. Daniel Tietjen and Daniel Dietrich

Federal Court of Justice Ruling on Public Advertising for Medical Cannabis on Online Platforms

by multiple authors

Proposed Amendments to the EU Medical Device Regulation

by Bartosz Świdrak

Impact of the new Biotech Act on Clinical Trials in the EU

by Irina Rebin

The 2026 Pharma Package: A New Regulatory Framework for Medicinal Products in the EU

by Irina Rebin

Life Sciences Legal Lens – Vol. 1

No claim for damages as a result of participation in clinical drug trials

by Irina Rebin